Bone-healing NMA separates modality effects from functional recovery. https://www.mattheneus.com/editorial/pubmed-electrical-stimulation-bone-healing-network-meta-analysis-modality-ranking-2026-10-07 #HTA #NMA #EvidenceSynthesis

Risk misclassification can reshape the value case for risk-stratified breast screening. https://www.mattheneus.com/editorial/risk-stratified-breast-screening-misclassification-capacity-cost-effectiveness-2026-10-01 #HTA #HealthEconomics #EvidenceSynthesis

A €607 annual price threshold sharpens the value case for empagliflozin after myocardial infarction. https://www.mattheneus.com/editorial/pubmed-empagliflozin-post-mi-heart-failure-risk-price-threshold-2026-10-05 #HTA #HealthEconomics #Pharma

Germany’s Lynkuet assessment shows how comparative follow-up duration can determine added-benefit conclusions. https://www.mattheneus.com/editorial/g-ba-elinzanetant-breast-cancer-endocrine-vasomotor-oasis4-duration-gap-2026-10-01 #HTA #Pharma #HealthEconomics

Intelligent-knife evidence now needs to connect diagnostic accuracy with surgical and patient outcomes. https://www.mattheneus.com/editorial/pubmed-intelligent-knife-cancer-surgery-diagnostic-outcomes-evidence-gap-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics

When can observational evidence credibly join randomised trials in one synthesis? A practical look at the decision. https://www.mattheneus.com/editorial/cochrane-grade-observational-randomised-evidence-integration-2026-10-05 #HTA #EvidenceSynthesis #RWE

Patient-relevant outcomes reach HTA decisions through four practical stages, from question framing to accountable use. https://www.mattheneus.com/editorial/ispor-patient-relevant-outcomes-four-stage-hta-framework-2026-10-06 #HTA #HealthEconomics #EvidenceSynthesis

IQWiG finds Alyftrek's added-benefit signal is limited to one cystic fibrosis genotype group. #HTA #Pharma #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-alyftrek-cystic-fibrosis-fmf-severe-exacerbation-signal-2026-10-01

Three reviews reveal a critical evidence gap in adult type 1 diabetes care in humanitarian settings. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/pubmed-type1-diabetes-humanitarian-settings-evidence-gap-systematic-reviews-2026-10-06

Tomorrow! Explore how #HTA institutional design affects pricing dynamics and time to access across Latin America. Learn more about the real-world trade-offs among methodological rigor, affordability, timely access, and innovation sustainability.

Register: https://ow.ly/6B0350ZOsV6

A 90-trial menopause review separates symptom effects from economic value. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/acp-menopause-vasomotor-pharmacologic-treatment-systematic-review-value-2026-10-06

A five-domain evidence map can make HTA planning more systematic and decision-ready. #HTA #EvidenceSynthesis #Pharma https://www.mattheneus.com/editorial/htai-five-domain-evidence-map-hta-planning-2026-10-05

Gene therapy could dominate factor prophylaxis in Sweden's haemophilia B model. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pubmed-etranacogene-dezaparvovec-sweden-haemophilia-b-cost-effectiveness-2026-10-04

Comparator choice drove Germany’s assessment of depemokimab in severe nasal polyposis. https://www.mattheneus.com/editorial/g-ba-depemokimab-crswnp-final-resolution-active-biologic-comparator-gap-2026-10-01 #HTA #Pharma #RegulatoryAffairs

Five-year follow-up reshaped the French value assessment of ribociclib in early breast cancer. https://www.mattheneus.com/editorial/has-kisqali-ribociclib-early-breast-cancer-five-year-natalee-reassessment-2026-09-16 #HTA #Pharma #HealthEconomics

A shared AI glossary can give evidence teams a clearer vocabulary for validation and governance. https://www.mattheneus.com/editorial/htai-generative-artificial-intelligence-glossary-validation-vocabulary-2026-10-05 #HTA #EvidenceSynthesis #RegulatoryAffairs

Sedentary-break frequency and intensity can change the treatment node, and the conclusions. A 72-trial network shows why dose definition matters. https://www.mattheneus.com/editorial/sedentary-interruption-nma-frequency-intensity-node-taxonomy-2026-10-01 #HTA #NMA #EvidenceSynthesis

A three-year colorectal screening model projects $12.5 million in savings, showing how budget impact analysis can guide adoption. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pubmed-next-generation-multitarget-stool-dna-idn-budget-model-2026-10-01

Across 29 studies, digital stroke programmes lowered short-term blood pressure, strengthening evidence for post-stroke support. #HTA #EvidenceSynthesis #RWE https://www.mattheneus.com/editorial/pubmed-poststroke-digital-interventions-blood-pressure-meta-analysis-2026-10-01

Polpril Nebi secured positive Polish reimbursement advice after bioequivalence and budget review. https://www.mattheneus.com/editorial/aotmit-polpril-nebi-final-positive-advice-budget-savings-2026-10-01 #HTA #Pharma #RegulatoryAffairs